Senti Biosciences (SNTI) AI Stock Analysis

• Market Cap: $20.77M
• Dividend Yield: N/A
• Average Volume (3M): 260.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: N/A
• EPS Growth: 78.60%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 26,290,838
• 10 Day Avg. Volume: 505,690
• 30 Day Avg. Volume: 260,000
• PEG Ratio: 0.05
• Price to Book (P/B): 41.84
• Price to Sales (P/S): 10628.51
• P/FCF Ratio: -5.36
• Enterprise Value/Market Cap: 1.60
• Enterprise Value/Revenue: 1.51K
• Enterprise Value/Gross Profit: -10.23
• Enterprise Value/Ebitda: -0.55
• 1Y Price Target: $12.00
• Price Target Upside: 1418.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.41
• Revenue Forecast (FY): $2.50M

• Rating: 43 Neutral
• Price Target: $0.85 ▲(7.59% Upside)
• Action: Reiterated Date: 03/27/26
• Date: Action: Reiterated 03/27/26

The score is held down primarily by very weak financial performance (zero recent revenue, large losses, and sustained cash burn) alongside heightened balance-sheet risk from sharply reduced equity and higher leverage. Technicals also lean bearish with the price below major moving averages and negative MACD. Valuation offers limited support given negative earnings and no stated dividend, while the recent lease restructuring is mixed but adds risk due to the letter-of-credit draw and GeneFab dependency.

Positive Factors

Regulatory Progress (RMAT)

RMAT designation is a structural regulatory advantage that can accelerate development and regulatory interactions for SENTI-202. It supports faster transition to pivotal studies and potential priority review, improving the company's strategic pathway to commercialization and partner interest.

Negative Factors

Sustained Cash Burn

Persistent negative operating and free cash flow means ongoing financing needs. Over the next 2–6 months this structural cash burn heightens refinancing and dilution risk, constrains R&D pacing, and forces strategic trade-offs if clinical programs require continued funding.

Senti Biosciences Business Overview & Revenue Model

Company Description

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to re...

Read more

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to re...

How the Company Makes Money

Senti Biosciences primarily generates revenue, if any, from collaboration and licensing arrangements (e.g., upfront payments, research funding/reimbursement, milestone payments, and royalties) rather than from product sales, because it is a clinic...

Read more

Senti Biosciences primarily generates revenue, if any, from collaboration and licensing arrangements (e.g., upfront payments, research funding/reimbursement, milestone payments, and royalties) rather than from product sales, because it is a clinic...

Senti Biosciences Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	22.00K	0.00	1.98M	3.29M	2.29M
Gross Profit	-3.62M	0.00	1.98M	3.29M	2.29M
EBITDA	-60.09M	-54.88M	-61.34M	-58.16M	-37.44M
Net Income	-61.44M	-52.79M	-71.06M	-58.21M	-55.32M
Balance Sheet
Total Assets	51.22M	97.84M	119.48M	180.79M	96.70M
Cash, Cash Equivalents and Short-Term Investments	16.42M	48.28M	35.93M	98.56M	56.03M
Total Debt	28.89M	33.64M	37.67M	37.09M	22.73M
Total Liabilities	45.63M	72.19M	52.57M	53.53M	36.33M
Stockholders Equity	5.59M	25.65M	66.91M	127.26M	60.38M
Cash Flow
Free Cash Flow	-43.64M	-41.42M	-64.43M	-76.27M	-40.18M
Operating Cash Flow	-43.44M	-41.40M	-52.40M	-34.90M	-34.63M
Investing Cash Flow	-184.00K	34.00K	30.08M	-81.96M	-5.54M
Financing Cash Flow	11.76M	53.73M	779.00K	118.55M	68.44M

Senti Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNTI, the sentiment is Negative. The current price of 0.79 is below the 20-day moving average (MA) of 0.93, below the 50-day MA of 0.95, and below the 200-day MA of 1.54, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 33.23 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNTI.

Senti Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TVRD	46 Neutral	$29.74M	-16.53	-135.79%	―	-53.67%	86.75%
KPTI	45 Neutral	$100.52M	-0.41	77.87%	―	-3.98%	-29.94%
BRNS	45 Neutral	$22.47M	-0.43	-70.57%	―	-100.00%	-26.30%
SNTI	43 Neutral	$20.77M	-3.81	-197.68%	―	―	78.60%
PSTV	43 Neutral	$39.46M	-17.81	774.80%	―	-8.16%	22.44%
IOBT	41 Neutral	$13.89M	-0.73	-465.36%	―	―	2.36%

Senti Biosciences Corporate Events